Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Int J Drug Policy. 2020 Sep 7;85:102934. doi: 10.1016/j.drugpo.2020.102934

Table 2.

Substance use behaviors among people who inject drugs residing in non-urban areas in the U.S. Northeast (N = 45).

Substances used, past 3 months (not mutually exclusive) n (%)
Heroin, fentanyl, or another synthetic opioid 42 (93)
Cocaine or crack cocaine 39 (87)
Cannabis 33 (73)
Benzodiazepines 27 (60)
Alcohol 19 (42)
Medication for opioid use disorder 17 (38)
Prescription opioids 12 (27)
Crystal methamphetamine 8 (18)
Prescription stimulants 5 (11)
Other drugs not prescribed 7 (13)
Drugs injected, past 3 months (not mutually exclusive) n (%)*
Heroin or fentanyl or another synthetic opioid 42 (100)
Cocaine or crack cocaine 28 (72)
Crystal methamphetamine 6 (75)
Prescription opioids 4 (33)
Benzodiazepines 2 (7)
Medication for opioid use disorder 2 (12)
Prescription stimulants 1 (20)
Other drugs not prescribed 2 (33)
Frequency of drug injection, past month n (%)
4 or more times a day everyday 14 (31)
1 to 3 times a day everyday 17 (38)
1 to 6 days a week 8 (18)
One day a month or less 6 (13)
Number of types of substances used, past 3 months** n (%)
2 2 (4)
3 12 (27)
4 7 (16)
5 10 (22)
6 9 (20)
7 or more 5 (11)
Number of types of substances injected, past 3 months** n (%)
1 14
2 23
3 6
4 2
*

Percentage of individuals who reported injecting these substances among those who reported using these substances

**

Classes of substances included: heroin or fentanyl; prescription opioids (e.g., oxycodone, hydrocodone); medication for opioid use disorder (e.g., methadone, buprenorphine); benzodiazepines; cocaine or crack cocaine; methamphetamines; prescription stimulants (e.g., methylfenidate, amphetamine); alcohol; cannabis; psychedelics (e.g., psilocybin mushrooms, dimethyltryptamine) and others (e.g., nitrates, sildenafil, sertraline, and synthetic cannabinoids).